Madrigal Pharma (MDGL) Announces Delay in Release of Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/26/2026

1. ON
2. SYNA
3. SPY
4. MU
5. VEON
6. DRI
7. NKE
8. NVDA
9. FDXF
10. QCOM

Go back to Madrigal Pharma (MDGL) Announces Delay in Release of Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
(NASDAQ: MDGL) Delayed: 525.43 +11.64 (2.27%)
Previous Close $513.79    52 Week High $18.24 
Open $517.66    52 Week Low $6.60 
Day High $532.33    P/E N/A 
Day Low $516.64    EPS $0.00 
Volume 143,805